قالب وردپرس درنا توس
Home / Business / With the rapid increase in the number of viruses and the development of COVID-19 vaccines, Bionatech has grown rapidly

With the rapid increase in the number of viruses and the development of COVID-19 vaccines, Bionatech has grown rapidly



Coronavirus disease vaccine
The photo illustration shows the syringe. Choose Argentina to test the vaccine against COVID-19, and it is estimated that the clinical phase will begin in August.

  • During the development of the updated COVID-19 vaccine, the shares of Moderna and BioNtech soared in Thursday trading.
  • With the surge of COVID-19 cases in the United States and Europe every day, investors are increasingly concerned about potential vaccines.
  • Moderna said it is “actively preparing to launch”
    ; its COVID-19 vaccine, and a report in the “Wall Street Journal” stated that Germany may begin vaccination with the BioNtech vaccine this year.
  • Visit the Business Insider homepage for more stories.

Moderna and BioNtech surged in Thursday’s trading, because investors are still paying more attention to a successful COVID-19 vaccine despite the surge in daily virus cases.

Moderna’s stock price rose by up to 13%, while BioNtech’s stock price rose by 11%.

Moderna said in its third-quarter earnings report that it is “actively preparing to launch” its COVID-19 vaccine.

The Phase III trial of Moderna’s vaccine candidate has fully recruited 30,000 patients.

To date, Moderna has received more than $1 billion in deposits from governments all over the world eager for a successful COVID-19 vaccine.

A recent deal reached by Moderna was with Japan’s Takeda, which was announced earlier today. Moderna will provide Takeda with 50 million doses of the COVID-19 vaccine in the first half of 2021, awaiting approval from Japan.

The Wall Street Journal reported on Thursday that, based on the results of clinical trials, BioNtech’s COVID-19 vaccine could be quickly distributed in Germany before the end of this year.

read more: Bank of the United States of America: Buy these 6 foods that are most suitable for Halloween celebrations at home, because towns curb trick-or-treating

According to people familiar with the strategy, a plan has been made to deliver a certain dose of BioNtech vaccine to more than 60 regional vaccine centers in Germany within an approved hour.

In Germany, the initial recipients of successful COVID vaccination include healthcare workers, the elderly and the clinically vulnerable population.

BioNtech has partnered with Pfizer to develop a COVID-19 vaccine and hopes to submit its vaccine for authorization in November.

According to the Wall Street Journal, BioNtech and Pfizer have produced millions of doses of vaccines, so they can be delivered in accordance with the pre-order contract.

The vaccine cannot come soon. The United States has experienced daily record numbers of virus cases over the past weekend, and Germany and France have adopted new lockdown measures in an attempt to contain the virus’s recovery.

read more: These are the six deadly suggestions provided by investment giants UBS and Barclays to trade European stocks after the US election


Source link